» Articles » PMID: 39347835

Unlocking the Potential: Unveiling Tyrphostins with Michael-reactive Cyanoacrylate Motif As Promising Inhibitors of Human 5-lipoxygenase

Overview
Journal Pflugers Arch
Specialty Physiology
Date 2024 Sep 30
PMID 39347835
Authors
Affiliations
Soon will be listed here.
Abstract

Human 5-lipoxygenase (5-LO) is the key enzyme in the biosynthesis of leukotrienes, mediators of the innate immune system that also play an important role in inflammatory diseases and cancer. In this study, we present compounds, containing a Michael-reactive cyanoacrylate moiety as potent inhibitors of 5-LO. Representatives of the tyrosine kinase inhibitor family called tyrphostins, structurally related to known 5-LO inhibitors, were screened for their 5-LO inhibitory properties using recombinant human 5-LO, intact human PMNL (polymorphonuclear leukocytes), and PMNL homogenates. Their mode of action was characterized by the addition of glutathione, using a fourfold cysteine 5-LO mutant and mass spectrometry analysis. SAR studies revealed several members of the tyrphostin family containing a Michael-reactive cyanoacrylate to efficiently inhibit 5-LO. We identified degrasyn (IC 0.11 µM), tyrphostin A9 (IC 0.8 µM), AG879 (IC 78 nM), and AG556 (IC 64 nM) as potent 5-LO inhibitors. Mass spectrometry analysis revealed that degrasyn and AG556 covalently bound to up to four cysteines, including C416 and/or C418 which surround the substrate entry site. Furthermore, the 5-LO inhibitory effect of degrasyn was remarkably impaired by the addition of glutathione or by the mutation of cysteines to serines at the surface of 5-LO. We successfully identified several tyrphostins as potent inhibitors of human 5-LO. Degrasyn and AG556 were able to covalently bind to 5-LO via their cyanoacrylate moiety. This provides a promising mechanism for targeting 5-LO by Michael acceptors, leading to new therapeutic opportunities in the field of inflammation and cancer.

Citing Articles

Lipid signaling: facets of a versatile cell communication strategy in health and disease.

Gulbins E, Pfeilschifter J Pflugers Arch. 2024; 476(12):1777-1778.

PMID: 39527143 PMC: 11582111. DOI: 10.1007/s00424-024-03034-8.

References
1.
Gazit A, Osherov N, POSNER I, Yaish P, Poradosu E, Gilon C . Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J Med Chem. 1991; 34(6):1896-907. DOI: 10.1021/jm00110a022. View

2.
Braeckman R, Granneman G, Locke C, MACHINIST J, Cavannaugh J, Awni W . The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet. 1995; 29 Suppl 2:42-8. DOI: 10.2165/00003088-199500292-00007. View

3.
Maucher I, Ruhl M, Kretschmer S, Hofmann B, Kuhn B, Fettel J . Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418. Biochem Pharmacol. 2016; 125:55-74. DOI: 10.1016/j.bcp.2016.11.004. View

4.
Levitzki A, Mishani E . Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem. 2006; 75:93-109. DOI: 10.1146/annurev.biochem.75.103004.142657. View

5.
Laughton M, Evans P, Moroney M, Hoult J, Halliwell B . Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ion-reducing ability. Biochem Pharmacol. 1991; 42(9):1673-81. DOI: 10.1016/0006-2952(91)90501-u. View